- - -

JOBS

EXECUTIVE JOBS

INVEST IN STOCKHOLM NEWSLETTER

SWEDISH WIRE NEWSLETTER

EMBASSIES/
CONSULATES
IN SWEDEN

RSS FEEDS

STOCKS

FLIGHTS, HOTELS AND HOLIDAYS

- - -
Investment opportunities

Tips from an insider: Five innovative tech startups

Tips from an insider: Stockholm tech start-ups

5 hot life science firms in Stockholm

Stockholm's top five infrastructure projects

Four Stockholm-based ICT firms to watch

Stockholm pioneers life science research

ICT startups offer investment opportunity

Swedish companies ready for exit

Five med-tech investment opportunities

Six cleantech investment opportunities

- - -
Rankings and surveys

Sweden tops English-language skills ranking

Sweden ranked world's best country to grow old

Swedish passport world's best for travellers

Sweden second best country for mothers

Stockholm climbs in competitiveness rankings

Sweden among best countries to be born

Fortune: 'Stockholm top place for startups'

Sweden tops first global Web Index

Sweden world's second most innovative country

Stockholm world's 6th 'best city'

'Cool Stockholm' most competitive Nordic capital

Sweden has (second) best reputation in the world

Sweden among top in Internet download speed

Sweden scores highest in 'Rule of law index'

Stockholm world's No1 in intellectual capital

Sweden the world's most ICT-competitive country

Sweden great place for moms – but Norway better

Swedes place 4th in English skills ranking

Sweden among top ICT countries

Sweden’s 10 greenest brands

‘Sweden needs to sell itself more’

Sweden overtakes the US in competitiveness

Sweden 10th ‘most admired country globally’

Sweden climbs in 'doing business' ranking

Sweden among world's least corrupt nations

Sweden's mortality rates world's second lowest

Sweden a good place to die – but Britain is best

Children in Sweden have best lives

Sweden the most competitive EU nation

Safe to do business with Swedes

How Sweden became an innovation frontrunner

Nordic countries world's most food-secure

Sweden the world’s best country – politically

Swedish firms among world's top brands

Swedish brands climb in global ranking

Sweden tops government ranking - while US lags 

'Swedish model' outranks 'American dream'  

Sweden among world's least corrupt nations

The Swedish Wire is a media production company that provides high-quality text, image and video content for international clients.

BioGaia AB: BioGaia's probiotic safe and effective in premature infants

Press release published at The Swedish Wire
Results from the largest probiotic study to date in premature infants showed that necrotizing enterocolitis (NEC), the most common gastrointestinal cause of death and illness in premature infants, decreased by 40% in the infants supplemented by Lactobacillus reuteri Protectis compared to placebo. Further, in the infants below 1500 grams Lactobacillus reuteri Protectis reduced episodes of feeding intolerance by 43%.

The safety of Lactobacillus reuteri Protectis in this high-risk population was also confirmed, but there was no significant difference between the groups on the primary outcome, frequency of death or hospital acquired infection.

"Although our study was under-powered to show significant differences in the primary outcome, the trends are consistent with those observed in meta analyses on NEC and death", says Professor Mario A. Rojas, Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem NC, United States.

"Unfortunately the study was terminated early, but despite this it is now confirmed that treatment of premature infants with Lactobacillus reuteri Protectis is both safe and clinically relevant", says Peter Rothschild, Chief Executive Officer at BioGaia.

Largest probiotic study in premature infants
A total of 751 infants were included in the study, which was considerably less than the number planned (1110) and required to reach significance in the outcome parameters. The study was terminated early, which was related to substantial drops in recruitment rate and funding restrictions from the independent funding institute.

In the multi-centre, double-blind, randomised, placebo-controlled trial in nine neonatal intensive care units in Colombia, infants born prematurely, with a birth weight of 2000 grams or smaller, were randomized to two groups, one that was given five drops daily of Lactobacillus reuteri Protectis (BioGaia ProTectis, n=372) and one that was given a corresponding placebo (n=378).

The study was published online in Pediatrics on 15 October 2012 (http://pediatrics.aappublications.org/content/early/2012/10/10/peds.2011-3584.abstract).

Necrotizing enterocolitis - a fatal disease
NEC is the death of intestinal tissue. It predominantly affects premature infants and often results in death or serious medical or neurodevelopmental complications, such as cerebral palsy (CP) and cognitive, visual or hearing impairment. The rate of NEC is highest in the smallest neonates (< 1500 grams) where around 10% of the infants are infected. The death rate ranges between 20 and 30%, with the highest rate among infants requiring surgery.

Lactobacillus reuteri  - a well researched probiotic
Lactobacillus reuteri is one of the world's most well researched probiotics, especially in young children. To date 92 clinical studies using BioGaia's human strains of Lactobacillus reuteri have been performed in more than 7,700 individuals of all ages. Half of the studies have been performed in premature babies, infants and children. Results are published in 63 articles in scientific journals (September 2012). 

Latest press releases from BioGaia
2012-10-12              BioGaia signs exclusive distribution agreement for its probiotic drops and tablets in Pakistan
2012-09-17              Lactobacillus reuteri Protectis shown to reduce colic in infants
2012-09-07              BioGaia's probiotic prevented necrotizing enterocolitis in high risk premature infants

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 15 October 2012, 15:30 am CET.

For additional information please contact
Peter Rothschild, President, BioGaia: +46 8 555 293 00
Mario A. Rojas, Dr, Department of Pediatrics, Wake Forest School of Medicine: mrojas@wakehealth.edu
Eamonn Connolly, Senior Vice President Research, BioGaia: +46 8 555 293 00

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
This information was distributed by Cision
 

Latest Jobs for English speakers in Sweden

Banner

Jobs for English speakers in Sweden

Banner
Banner
Most Read Searched  
Banner
Banner
Banner